Valeant proposes Allergan deal

Article

Late yesterday afternoon, Valeant Pharmaceuticals announced that it had proposed a merger with Allergan.

 

Late yesterday afternoon, Valeant Pharmaceuticals announced that it had proposed a merger with Allergan.

Allergan’s largest shareholder (9.7%), Pershing Square Capital Management, managed by Bill Ackman, supports the initiative, according to Bloomberg. In addition, Mr. Ackman believes that Allergan is undervalued and worked with Valeant to cooperatively engage in a hostile takeover of Allergan.

Yesterday, according to the Wall Street Journal, Valeant offered Allergan $48.30 and 0.83 Valeant shares per Allergan share.

Allergan’s stock price was $116.63 on April 10, the day before Mr. Ackman began rapidly accumulating shares. It increased to $166.41 after news broke of Valeant’s interest.

Valeant finalized its acquisition of Bausch + Lomb in August 2013.ODT

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.